Rocket Pharmaceuticals (RCKT) Cash from Operations (2014 - 2026)

Rocket Pharmaceuticals has disclosed Cash from Operations across 13 years of filings, most recently posting 45394000.0 for Q1 2026.

• Cash from Operations for Q1 2026 came in at 45394000.0, up 18.63% year-over-year; the trailing twelve-month figure through Mar 2026 was 179618000.0 (up 13.92% YoY), and the FY2025 annual result was 190014000.0, up 9.4% from the prior year.
• Cash from Operations came in at 45394000.0 for Q1 2026 at Rocket Pharmaceuticals, down from 34840000.0 in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of 29339000.0 in Q4 2023 to a low of 57560000.0 in Q1 2023.
• The 5-year median for Cash from Operations is 50420000.0 (2025), against an average of 48128823.53.
• Across the five-year window, Cash from Operations sank 81.06% in 2022 and jumped 47.63% in 2023, its largest moves.
• Rocket Pharmaceuticals' Cash from Operations stood at 56021000.0 in 2022, then surged by 47.63% to 29339000.0 in 2023, then plunged by 60.0% to 46942000.0 in 2024, then climbed by 25.78% to 34840000.0 in 2025, then slumped by 30.29% to 45394000.0 in 2026.
• The last three Cash from Operations figures came in at 45394000.0 (Q1 2026), 34840000.0 (Q4 2025), and 50420000.0 (Q3 2025), per Business Quant data.